Results 101 to 110 of about 11,822 (164)
Combination of Upadacitinib and Risankizumab in Refractory Crohn's Disease
JCC Plus, Volume 1, Issue 3, May 2026.ABSTRACT Background and Aim Dual targeted therapies (DTT) are a promising off‐label approach for the treatment of refractory Crohn's disease (CD). Upadacitinib and risankizumab are approved for the treatment of moderate to severe CD. Our aim was to evaluate the effectiveness and safety of a combination of upadacitinib and risankizumab for refractory CD.
Clara Ramos‐Belinchon +5 more
wiley +1 more source
A Distinct Tryptophan Metabolic Phenotype Marks Severe Fatigue in Quiescent Crohn's Disease
JCC Plus, Volume 1, Issue 3, May 2026.ABSTRACT Background Fatigue is a common and debilitating symptom in inflammatory bowel disease (IBD), but its underlying mechanisms remain unclear. Altered tryptophan metabolism may contribute to fatigue. Tryptophan is metabolized through the kynurenine, serotonin, and indole pathway, involving host and microbial processes. We aimed to explore the link
Paula I. Metselaar +12 more
wiley +1 more source
A novel diagnostic serum protein signature for pediatric inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 5, Page 1208-1217, May 2026.Abstract Objectives Diagnostic delay is common in pediatric inflammatory bowel disease (PIBD), and fecal calprotectin (FCP) is often limited by challenges with sample collection. Therefore, we aimed to identify and validate a blood‐based diagnostic protein signature of PIBD.
Charlotte Bache‐Wiig Mathisen +22 more
wiley +1 more source
Dog attacks on wild desert tortoises: A risk model
The Journal of Wildlife Management, Volume 90, Issue 4, May 2026.Domestic dogs attack and severely injure wild desert tortoises at the urban and ex‐urban interface with deserts. Severe trauma to tortoises increased 4 times to shell and limbs and 16.5 times to the gular horn over the decades between the 1970s and 2000s. Tortoises were at exponential risk of severe trauma when living within 12 km of settlements, towns,
Andrea S. Carlson +2 more
wiley +1 more source
Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70
MedComm, Volume 7, Issue 5, May 2026.This work presents a novel CAR NK cell platform targeting membrane‐bound Hsp70, a tumor‐specific antigen broadly expressed on solid tumors but not on normal cells. Computational modeling confirmed strong binding between the CAR construct and the Hsp70‐derived TKD peptide.
Khouloud Hachani +17 more
wiley +1 more source
First whole-genome assembly of the Galápagos Petrel (Pterodroma phaeopygia) using Oxford Nanopore sequencing to advance conservation genomics in a critically endangered seabird. [PDF]
G3 (Bethesda)Sessi IR +8 more
europepmc +1 more source
United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.ABSTRACT Background Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF.
Ailsa Hart +15 more
wiley +1 more source
Haematology and biochemistry reference intervals of Galapagos short-eared owls (<i>Asio flammeus galapagoensis</i>) from Floreana Island. [PDF]
Conserv PhysiolVaasjo E +7 more
europepmc +1 more source
United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra +51 more
wiley +1 more source